Entrada Therapeutics Announces Independent Data Monitoring Committee Review Of All Available Safety And PK Data From The Eight Participants Enrolled In Cohort 2 Of The Double-Blind, Placebo-Controlled, Multiple Ascending Dose Portion of ELEVATE-44-201
